Analyzing Adagio Medical (ADGM) and Its Rivals

Adagio Medical (NASDAQ:ADGM) is one of 142 publicly-traded companies in the “MED INSTRUMENTS” industry, but how does it weigh in compared to its rivals? We will compare Adagio Medical to similar businesses based on the strength of its risk, earnings, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Volatility & Risk

Adagio Medical has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, Adagio Medical’s rivals have a beta of 1.92, indicating that their average stock price is 92% more volatile than the S&P 500.

Profitability

This table compares Adagio Medical and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adagio Medical	N/A	-248.26%	-125.31%
Adagio Medical Competitors	-182.40%	-90.47%	-20.57%

Insider & Institutional Ownership

48.1% of Adagio Medical shares are owned by institutional investors. Comparatively, 54.1% of shares of all “MED INSTRUMENTS” companies are owned by institutional investors. 53.5% of Adagio Medical shares are owned by company insiders. Comparatively, 14.7% of shares of all “MED INSTRUMENTS” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Adagio Medical and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagio Medical	1	0	0	0	1.00
Adagio Medical Competitors	1149	3775	7096	261	2.53

As a group, “MED INSTRUMENTS” companies have a potential upside of 22.15%. Given Adagio Medical’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Adagio Medical has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares Adagio Medical and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Adagio Medical	$600,000.00	-$75.04 million	-2.04
Adagio Medical Competitors	$1.72 billion	$195.96 million	-3.48

Adagio Medical’s rivals have higher revenue and earnings than Adagio Medical. Adagio Medical is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Adagio Medical rivals beat Adagio Medical on 10 of the 13 factors compared.

About Adagio Medical

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. The company is based in Laguna Hills, California.